Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annovis Bio, Inc.ANVS · Entity 7001 | Director | May 20, 2026 | May 22, 2026 |
| Embark Technology, Inc.NGAB.U · Entity 110807 | President | January 12, 2021 | January 13, 2021 |
| Northern Genesis Acquisition Corp.NGA.U · Entity 139591 | President | August 17, 2020 | August 17, 2020 |
| Northern Genesis Acquisition Corp. IIINGC.U · Entity 140918 | President | March 23, 2021 | March 24, 2021 |
| Translational Development Acquisition Corp.TDAC · Entity 6290 | Director · Chairman and CEO | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annovis Bio, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,364,883 |
Ending reported balance
After 2026-05-20 transaction · row 4
3 source rows · reconciled sequenceRow 1 · 2026-05-20 · Purchase · Acquired 2,562 · Balance 3,291,101 Row 3 · 2026-05-20 · Purchase · Acquired 18,849 · Balance 3,309,950 Row 4 · 2026-05-20 · Purchase · Acquired 54,933 · Balance 3,364,883 |
| Common StockSEC Table I · non-derivative | IndirectThe 2024 Hoffman Family Trust | 223,357 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 223,357 F1: The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.
Embark Technology, Inc.
Report date January 12, 2021 · Filed January 13, 2021
This filing explicitly reported no securities owned.
Northern Genesis Acquisition Corp.
Report date August 17, 2020 · Filed August 17, 2020
This filing explicitly reported no securities owned.
Northern Genesis Acquisition Corp. III
Report date March 23, 2021 · Filed March 24, 2021
This filing explicitly reported no securities owned.
Translational Development Acquisition Corp.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 53,395 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Purchase · Acquired 53,395 · Balance 53,395 F2: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.71 to $0.9997, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of warrants purchased at each separate price within the range set forth in this footnote. For reference, aggregate proceeds were $42,280.50 and the exact weighted average price was $0.7918438056. F1: Each warrant becomes exercisable 30 days after completion of the Issuer's initial business combination, as described in the Issuer's filings with the Securities and Exchange Commission. The warrants expire five years after completion of the Issuer's initial business combination, or earlier upon redemption or liquidation, as described in the Issuer's filings with the Securities and Exchange Commission (the "SEC") |
Filing footnotes · ownership attribution and instrument terms
F1: Each warrant becomes exercisable 30 days after completion of the Issuer's initial business combination, as described in the Issuer's filings with the Securities and Exchange Commission. The warrants expire five years after completion of the Issuer's initial business combination, or earlier upon redemption or liquidation, as described in the Issuer's filings with the Securities and Exchange Commission (the "SEC")
F2: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.71 to $0.9997, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of warrants purchased at each separate price within the range set forth in this footnote. For reference, aggregate proceeds were $42,280.50 and the exact weighted average price was $0.7918438056.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Traws Pharma, Inc.
Report date August 27, 2020 · Filed August 31, 2020
Section 16 reporting ended · disclosed 2020-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Michael and Jane Hoffman 2013 Descendants Trust | 21,919 |
Reported balance
After 2020-08-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-08-27 · Sale · Disposed 182,492 · Balance 21,919 F1: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-27 transaction · row 2
1 source rowRow 2 · 2020-08-27 · Sale · Disposed 1,876 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy the Michael and Jane Hoffman 2013 Descendants Trust(Non-GST Exempt Trust) | 564 |
Reported balance
Holding disclosure · report date 2020-08-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 564 F1: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2020 Filed Feb 5, 2020 11:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 1,137,942 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-010943 · a4.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 158,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-010943 · a4.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 33,333 | $6.00 | $199,998.00 |
DisclosureSEC source: 0001104659-20-010943 · a4.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,619 F1 · shares: The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis"). Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 21:26 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 5,833 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001179110-19-008869 · edgar.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,833 Underlying: Common Stock · 5,833 shares Expires 2029-07-26 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| August 29, 2018 Filed Aug 29, 2018 21:22 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 29,999.262 | $0.45 | $13,520.67 |
DisclosureSEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust Disclosed balance after: 5,731,116.738 F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor. F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 21:22 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 30,000 | $0.46 | $13,707.00 |
DisclosureSEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust Disclosed balance after: 5,761,116 F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor. F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 21:22 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 20,000 | $0.44 | $8,890.00 |
DisclosureSEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust Disclosed balance after: 5,791,116 F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor. F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 21:22 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 20,000 | $0.45 | $9,070.00 |
DisclosureSEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust Disclosed balance after: 5,811,116 F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor. F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 21:34 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 87,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001179110-18-010016 · edgar.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2028-07-26 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| April 27, 2018 Filed May 1, 2018 22:34 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseWarrant (right to purchase) · Derivative | 2,211,765 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006018 · edgar.xml · derivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2013 Descendants Trust Disclosed balance after: 2,211,765 Underlying: Series B Convertible Preferred Stock · 55,294.13 shares Expires not disclosed F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315). F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware. F3 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. Read SEC document |
| April 27, 2018 Filed May 1, 2018 22:34 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 2,211,765 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-006018 · edgar.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2013 Descendants Trust Disclosed balance after: 3,192,438 F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315). F3 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:08 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 2,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008999 · edgar.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.